Tonix Pharmaceuticals Holding Corp

NASDAQ:TNXP  
1.06
+0.09 (+9.28%)
Products, Regulatory

Tonix Pharmaceuticals Announces Positive Phase 3 Relief Study Results For TNX-102 SL 5.6 Mg In Fibromyalgia

Published: 12/07/2020 12:32 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Announces Positive Phase 3 Relief Study Results for Tnx-102 Sl 5.6 Mg in Fibromyalgia.
Tonix Pharmaceuticals Holding Corp - New 5.6 Mg Dose Achieved Statistically Significant Pain Reduction Over Placebo at Week 14.
Tonix Pharmaceuticals Holding Corp - Tnx-102 Sl Generally Well Tolerated With Adverse Event Profile Comparable to Prior Studies.
Tonix Pharmaceuticals Holding Corp - Expect to Report Data From Second Potential Pivotal Phase 3 Study in Second Half of 2021.
Tonix Pharmaceuticals Holding Corp - May Be in Position to Submit a NDA for Tnx-102 Sl for Fibromyalgia to U.S. FDA in 2022.
Tonix Pharmaceuticals Holding Corp - Additionally, Believe Commercial Manufacturing for Tnx-102 Sl is on Track to Supply U.S. Market in 2022.